Jump to content

Deuruxolitinib

From Wikipedia, the free encyclopedia

Deuruxolitinib
Clinical data
Trade namesLeqselvi
Other namesCTP-543
AHFS/Drugs.comLeqselvi
License data
Routes of
administration
By mouth
Drug classJanus kinase inhibitor
ATC code
  • None
Legal status
Legal status
Identifiers
  • (3R)-3-(2,2,3,3,4,4,5,5-Octadeuteriocyclopentyl)-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
ChEMBL
Chemical and physical data
FormulaC17H18N6
Molar mass306.373 g·mol−1
3D model (JSmol)
  • [2H]C1(C(C(C(C1([2H])[2H])([2H])[2H])([2H])[2H])[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3)[2H]
  • InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1/i1D2,2D2,3D2,4D2
  • Key:HFNKQEVNSGCOJV-FBXGHSCESA-N
  • Key:JFMWPOCYMYGEDM-NTVOUFPTSA-N

Deuruxolitinib, sold under the brand name Leqselvi, is a medication used for the treatment of alopecia areata.[1] It is a Janus kinase inhibitor selective for JAK1 and JAK2.[2] Although the relative effectiveness of deuruxolitinib and another Janus kinase inhibitor—baricitinib—for alopecia areata may vary depending on the population studied, both drugs are more effective than alternative treatments.[3]

Deuruxolitinib was approved for medical use in the United States in July 2024.[1][4]

Medical uses

[edit]

Deuruxolitinib is indicated for the treatment of adults with severe alopecia areata.[1]

Side effects

[edit]

The FDA prescribing label for deuruxolitinib contains a boxed warning for serious infections; malignancies; cardiovascular death, myocardial infarction, and stroke; and thrombosis.[5]

Society and culture

[edit]

Names

[edit]

Deuruxolitinib is the international nonproprietary name[6] and the United States Adopted Name.[7]

References

[edit]
  1. ^ a b c d "Archived copy" (PDF). Archived (PDF) from the original on 29 July 2024. Retrieved 26 July 2024.{{cite web}}: CS1 maint: archived copy as title (link)
  2. ^ King, Brett; Mesinkovska, Natasha; Mirmirani, Paradi; Bruce, Suzanne; Kempers, Steve; Guttman-Yassky, Emma; et al. (August 2022). "Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areata". Journal of the American Academy of Dermatology. 87 (2): 306–313. doi:10.1016/j.jaad.2022.03.045. ISSN 1097-6787. PMID 35364216. S2CID 247866262.
  3. ^ SEDEH, Farnam Barati; MICHAELSDÓTTIR, Thorunn Elísabet; HENNING, Mattias Arvid Simon; JEMEC, Gregor Borut Ernst; IBLER, Kristina Sophie (25 January 2023). "Comparative Efficacy and Safety of Janus Kinase Inhibitors Used in Alopecia Areata: A Systematic Review and Meta-analysis". Acta Dermato-Venereologica. 103: 4536. doi:10.2340/actadv.v103.4536. ISSN 0001-5555. PMC 10391778. PMID 36695751.
  4. ^ "U.S. FDA Approves Leqselvi (deuruxolitinib), an Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata" (Press release). Sun Pharmaceutical. 25 July 2024. Archived from the original on 26 July 2024. Retrieved 26 July 2024 – via PR Newswire.
  5. ^ http://www.leqselvi.com/&a=Prescribing Information
  6. ^ World Health Organization (2021). "International nonproprietary names for pharmaceutical substances (INN): recommended INN: list 86". WHO Drug Information. 35 (3). hdl:10665/346562.
  7. ^ "Deuruxolitinib". American Medical Association. Retrieved 27 July 2024.

Further reading

[edit]
[edit]